Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 13/20 | 0.52 |
| ▸ | CTSK | P43235 | 12/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9980623 | 0.92 | MEN1 (0.62) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL16909076 | 0.91 | MEN1 (0.57) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL8183191 | 0.91 | MEN1 (0.57) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL18919537 | 0.87 | CTSK (0.64) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL18919536 | 0.87 | CTSK (0.64) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL17109074 | 0.87 | CTSK (0.64) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL18281226 | 0.86 | MEN1 (0.61) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL2850443 | 0.86 | MEN1 (0.61) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL1003435 | 0.86 | MEN1 (0.61) | KMT2AMEN1GAACTSSCTSK | |
| SCHEMBL33528044 | 0.86 | CTSK (0.49) | KMT2AMEN1GAACTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741834-B2 | Dipeptoid prodrugs and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | Bayer Schering Pharma | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | DPP4, DPP3, DNPEP | KMT2A 3242/4885MEN1 2410/4885GAA 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.